Updated:
4D Molecular Therapeutics
Founded in 2013 by Dr. David Kirn and Dr. Melissa Kotterman, 4D Molecular Therapeutics emerged from the University of California, Berkeley's gene therapy...
4D Molecular Therapeutics
Founded in 2013 by Dr. David Kirn and Dr. Melissa Kotterman, 4D Molecular Therapeutics emerged from the University of California, Berkeley's gene therapy research ecosystem. Kirn, a virologist and former head of oncology at AstraZeneca's MedImmune, and Kotterman, whose graduate work pioneered directed evolution of AAV capsids, built the firm on the premise that off-the-shelf viral vectors were the primary bottleneck in gene therapy. The wealth backing the firm traces to venture capital — Deerfield Management, PBM Capital, and Viking Global Investors led early rounds — rather than a single-family fortune. The company's therapeutic vector evolution platform generates customized adeno-associated virus (AAV) capsids capable of crossing tissue barriers that conventional vectors cannot. Its clinical pipeline targets three distinct therapeutic areas: ophthalmology, pulmonology, and cardiology. Lead candidate 4D-150 delivers a dual transgene for wet AMD and diabetic macular edema, while 4D-710 addresses cystic fibrosis lung disease via aerosolized delivery. The firm conducts clinical operations in the United States and Europe, with manufacturing split between in-house process development and contract partners. Unlike many gene therapy platforms that in-license vectors, 4DMT owns full IP on its evolved capsids, giving it a negotiating position with commercial partners including Astellas Pharma for rare ophthalmic indications (per the firm's SEC filings, 2023). As of early 2024, 4DMT employed approximately 200 professionals at its Emeryville headquarters. The firm raised roughly $350 million in total financing before its 2020 Nasdaq IPO, with additional capital accessed through follow-on offerings and partnership milestones. In February 2024, the firm reported positive interim Phase 2 data for 4D-150 in wet AMD, showing sustained aflibercept-like efficacy with reduced injection frequency — an event that shifted institutional perception of the platform's clinical proof. The company maintains no philanthropic foundation, instead funneling resources entirely toward clinical development and manufacturing scale-up. The structural distinction is 4DMT's dual identity: it functions as a publicly traded drug developer with clinical risk, not a diversified asset manager. This means allocators encounter it as an equity holding, not a partnership commitment. The firm's governance centers on a management team with deep biopharma operating experience — CEO Kirn previously co-founded Onyx Pharmaceuticals and oversaw the approval of Kyprolis — rather than a capital-deployment committee. Its value proposition rests not on deal flow or fund structure, but on whether its engineered capsids can deliver genetic payloads more safely and effectively than competing platforms from Sarepta, BioMarin, or Pfizer.
General information
Firm type
Asset Manager
Year founded
2013
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Emeryville
Corporate office
Emeryville, CA, United States
Principals
David Kirn
Co-Founder and Chief Executive Officer
Melissa Kotterman
Co-Founder and Chief Scientific Officer
Sector focus
Frequently asked questions
Who runs investment decisions at 4D Molecular Therapeutics?
4DMT is not an investment firm. It is a clinical-stage biotech company that deploys its own balance sheet toward drug development. Capital allocation decisions rest with CEO David Kirn and the board of directors, with major strategic moves — clinical trial initiations, partnership structures, follow-on equity offerings — subject to board approval. The firm does not accept external discretionary capital; it raises funds through equity markets and pharmaceutical partnerships.
How does 4D Molecular Therapeutics source proprietary deal flow?
The company does not source deal flow in the allocator sense. As a drug developer, it generates pipeline candidates through its own therapeutic vector evolution platform rather than acquiring external programs. Its competitive moat lies in the directed evolution of AAV capsids — a process that creates custom viral shells capable of delivering genetic payloads to tissues that conventional vectors cannot reach efficiently, such as the retina and lung epithelium.
Is 4D Molecular Therapeutics structured as a family office or does it operate more like a venture firm?
Neither. 4DMT is a publicly traded biopharmaceutical company listed on Nasdaq under the ticker FDMT. It operates as a clinical-stage drug developer with three active INDs and no external capital management function. Institutional investors gain exposure by purchasing common stock, not through LP commitments. The firm's venture capital relationships — Deerfield, PBM, Viking — were early equity backers rather than ongoing allocators.
Does 4D Molecular Therapeutics participate in fund commitments or only direct deals?
The company does not make fund commitments or invest in external deals. It uses its capital to advance wholly owned gene therapy programs from discovery through clinical trials. When it forms partnerships — such as the collaboration with Astellas on rare ophthalmic targets — it receives milestone payments and royalties, not portfolio diversification.
What investment stages does 4D Molecular Therapeutics typically target?
4DMT is not a stage investor. It develops therapies from preclinical research through Phase 3 trials using its own platform and balance sheet. Outside investors participate by buying equity at the company's current market capitalization, which embeds both the pipeline's optionality and the binary risk of clinical readouts. The firm has not historically deployed third-party capital into other biotech startups.
Which sectors does 4D Molecular Therapeutics explicitly avoid?
The firm has no announced investment activity or capital deployment outside gene therapy. All pipeline programs target diseases addressable with AAV-mediated gene delivery, meaning oncology, infectious disease, and small-molecule drug discovery fall entirely outside its scope. Its platform focuses on ophthalmology, pulmonology, and cardiology — indications where local delivery of genetic payloads offers a clear therapeutic rationale.
Where does the underlying wealth come from?
4DMT has no single-family wealth origin. The firm was built with venture capital from institutional healthcare investors including Deerfield Management, PBM Capital Group, and Viking Global Investors. It went public in December 2020, raising $222 million in its IPO, and has since raised additional capital through follow-on equity offerings and partnership economics.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: